| Article
2018 was not a good year to be on the wrong side of medical necessity when it came to drug testing and ongoing prescribing of controlled medication or substance abuse treatment programs. 2019 is likely to be an expensive year for those who do not proactively take steps to understand medical...
| Article
The subject of the medical use of cannabinoids has become an extremely hot topic. Unfortunately, there has been a tendency to equate medical cannabinoids with another very contentious topic: Medical Marijuana. In this presentation, the distinction between medical cannabinoids and medical cannabis...
| Article
Marijuana (MJ) and hemp are genetically distinct cousins of the genus Cannabis sativa L., yet they have been erroneously associated with each other for the past 80 years. That all changed in December 2018 when Congress removed hemp from the federal Controlled Substances Act (CSA) and legalized the...
| Article
Overdose—a small word that packs a major punch, and a big reason for many recent legal regulatory changes in controlled substance prescribing and pain management. Too many physicians and allied healthcare practitioners are caught unawares by the legal issues surrounding overdose events, fatal and...
| Article
On September 16, 2015, the Centers for Disease Control and Prevention (CDC), hosted a semi-public webinar where they revealed a draft of their twelve (12) prescribing guidelines for chronic pain. After concerns over the limited amount of participation was raised by the pain community, and following...
| Article
Breakfast will be served.
Sponsored by Daiichi Sankyo, Inc.
| Article
On March 15, 2016, the Centers for Disease Control and Prevention released their guideline with recommendations for primary care clinicians who prescribe opioids for chronic pain outside of active cancer treatment, palliative care, and end-of-life care. Although most of the recommendations were...